Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon Tissues
Credit: Zurich University of Applied Sciences (ZHAW)
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening.
In a new SLAS Technology original research article available now for free ahead-of-print, researchers in Switzerland describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting. The novelty and importance of this new approach is the combination of the automated musculoskeletal tissue production using 3D bioprinting with a new microwell plate addressing the specific tissue attachment requirements. Thus, this screening platform represents a promising new tool for musculoskeletal drug discovery and development.
Muscle and tendon tissue models are fabricated by printing alternating layers of photo-polymerized gelatin-methacryloyl-based bioink and cell suspensions in a dumbbell shape onto a newly designed cell culture insert in 24-well plates containing two vertical posts. The cells show high viability after printing in culture and good tissue differentiation based on marker gene and protein expressions.
In addition, functionality of the muscle tissue models is demonstrated by calcium signaling of Fluo4-loaded cells and myofiber contractility induced by electrical pulse stimulation. Finally, the authors successfully fabricate tendon-muscle-tendon co-cultures by printing tenocytes around the posts of the cell culture inserts and myoblasts between the posts.
This article has been republished from materials provided by SLAS. Note: material may have been edited for length and content. For further information, please contact the cited source.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019